Madopar (Benserazide Hydrochloride, Levodopa)

Levodopa serves as a precursor that crosses the blood‑brain barrier and is converted into dopamine, the neurotransmitter lacking in Parkinsonian conditions. Benserazide inhibits peripheral decarboxylation of levodopa, ensuring more of the drug reaches the central nervous system where it can be transformed into dopamine.

The appropriate dose of Madopar is individualized by the prescribing clinician based on disease severity, patient age, and response to therapy. Dosage adjustments are made during treatment to achieve optimal symptom control while minimizing side effects.

Safety data for Madopar in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Madopar, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Madopar combines levodopa with benserazide, offering higher central availability of levodopa compared with levodopa alone. Compared with dopamine agonists, it provides more potent symptom relief but may have a higher incidence of motor complications such as dyskinesia. Choice of therapy depends on individual patient factors and treatment goals.

Madopar should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product away from excessive heat and humidity to maintain stability throughout its shelf life.

Madopar is taken orally, usually with a glass of water. It may be administered with or without food, but consistent timing relative to meals can help reduce gastrointestinal side effects. The exact schedule is determined by the prescribing clinician.

Serious risks include the development of dyskinesia, hallucinations, severe hypotension, neuroleptic malignant syndrome, and rare allergic reactions such as anaphylaxis. Patients should be monitored regularly for these events, and any concerning symptoms should prompt immediate medical evaluation.

Madopar is contraindicated in patients with known hypersensitivity to levodopa, benserazide, or any excipients in the formulation. It should also be avoided in individuals taking non‑selective MAO inhibitors or those with narrow‑angle glaucoma, as it may exacerbate the condition.